Hospital
Centra Health INC
Centra Health INC was paid $18.47M by Medicaid between Jan 2018 and Dec 2024, across 217 billing codes. Its largest line is 96361, Intravenous infusion, hydration; each additional hour — 18% of everything it billed.
33Billing provider infoCENTRA HEALTH INC
LYNCHBURG, VA 24501
LYNCHBURG, VA 24501
33aNPI1679677983assigned 09/08/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$18.47M
24GClaims468,054
24DCodes billed217
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Virginia
Rank by total paid#35 of 80
Median peer was paid$14.69M
This provider vs. median1.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ADDISON, LEWIS controls 12+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 36,638 | $615K | |
| 2019 | 87,087 | $1.98M | |
| 2020 | 94,307 | $3.95M | |
| 2021 | 103,340 | $4.38M | |
| 2022 | 70,293 | $3.21M | |
| 2023 | 36,292 | $1.90M | |
| 2024incomplete | 40,097 | $2.43M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 96361 | Intravenous infusion, hydration; each additional hour | 18% | 10,031 | 7,676 | $3.31M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14% | 16,862 | 14,545 | $2.67M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 17,548 | 14,732 | $2.52M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 17,452 | 15,142 | $2.45M |
| G0378 | Hospital observation service, per hour | 3.7% | 3,012 | 2,468 | $682K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.2% | 3,028 | 2,730 | $599K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.2% | 3,300 | 2,934 | $596K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.8% | 1,833 | 1,645 | $516K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.3% | 3,067 | 2,711 | $419K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.2% | 3,939 | 2,982 | $415K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.2% | 6,132 | 4,637 | $409K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 2.0% | 2,905 | 2,468 | $370K |
205 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.8% | 2,536 | $330K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.6% | 1,652 | $295K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.5% | 5,096 | $282K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.2% | 1,060 | $228K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.1% | 1,436 | $199K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 889 | $170K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,868 | $168K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,599 | $165K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 681 | $158K |
| 80053 | Comprehensive metabolic panel | <1% | 31,241 | $152K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,416 | $132K |
| 59025 | Fetal non-stress test | <1% | 739 | $125K |
| 93971 | <1% | 870 | $96K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 913 | $84K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 500 | $75K |
| 93017 | <1% | 291 | $63K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 660 | $61K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,543 | $52K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 10,114 | $42K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 11,318 | $40K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,134 | $38K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 512 | $33K |
| 83880 | <1% | 2,284 | $27K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,527 | $25K |
| 80329 | <1% | 1,646 | $23K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,500 | $21K |
| 70496 | <1% | 72 | $21K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 135 | $20K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 994 | $18K |
| 93246 | <1% | 262 | $18K | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 746 | $17K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 28,413 | $17K |
| 84484 | <1% | 11,315 | $14K | |
| 93000 | <1% | 6,635 | $13K | |
| 87040 | <1% | 1,298 | $13K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 963 | $11K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 13 | $11K |
| 85380 | <1% | 1,534 | $10K | |
| 74018 | <1% | 623 | $10K | |
| 93325 | <1% | 247 | $9K | |
| 90715 | <1% | 529 | $9K | |
| 93320 | <1% | 29 | $9K | |
| 70498 | <1% | 174 | $9K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 40 | $9K |
| 80061 | Lipid panel | <1% | 1,477 | $9K |
| 96367 | <1% | 1,512 | $9K | |
| 76801 | <1% | 128 | $8K | |
| J3490 | Unclassified drugs | <1% | 3,533 | $8K |
| 36415 | Collection of venous blood by venipuncture | <1% | 14,445 | $8K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,383 | $7K |
| 97161 | <1% | 196 | $7K | |
| 80047 | <1% | 1,374 | $7K | |
| 85027 | <1% | 8,891 | $6K | |
| 76641 | <1% | 56 | $5K | |
| 71045 | Radiologic examination, chest; single view | <1% | 2,350 | $5K |
| 0296T | <1% | 367 | $5K | |
| A0425 | Ground mileage, per statute mile | <1% | 273 | $5K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,968 | $4K |
| 80320 | <1% | 2,926 | $4K | |
| 0002A | <1% | 110 | $4K | |
| 82962 | <1% | 6,752 | $3K | |
| 81001 | <1% | 18,705 | $3K | |
| 0001A | <1% | 126 | $3K | |
| 93242 | <1% | 35 | $3K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,789 | $3K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,628 | $3K |
| 72100 | <1% | 552 | $3K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 141 | $3K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 38 | $2K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 559 | $2K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 763 | $2K |
| 99070 | <1% | 521 | $2K | |
| 83605 | <1% | 3,056 | $2K | |
| 85610 | <1% | 3,888 | $2K | |
| 93970 | <1% | 15 | $2K | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 117 | $2K |
| 93296 | <1% | 93 | $2K | |
| 73030 | <1% | 592 | $2K | |
| 76770 | <1% | 12 | $2K | |
| 77066 | Tomosynthesis, mammo | <1% | 50 | $2K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,509 | $2K |
| 86900 | <1% | 1,166 | $2K | |
| 83690 | <1% | 7,373 | $2K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 10,815 | $2K |
| 86850 | <1% | 684 | $2K | |
| 83735 | <1% | 3,985 | $1K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 10,257 | $1K |
| 73610 | <1% | 581 | $1K | |
| 87081 | <1% | 3,048 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,870 | $1K |
| 97116 | <1% | 19 | $1K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,638 | $1K |
| 73630 | <1% | 542 | $1K | |
| 90686 | <1% | 58 | $1K | |
| 73564 | <1% | 502 | $920.91 | |
| 86901 | <1% | 1,165 | $886.35 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 87 | $854.51 |
| 84702 | <1% | 1,187 | $850.99 | |
| A0427 | Emergency ambulance ride, advanced life support | <1% | 15 | $818.48 |
| 82803 | <1% | 1,914 | $788.86 | |
| 86140 | <1% | 672 | $749.39 | |
| 73130 | <1% | 364 | $748.50 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 9,265 | $737.41 |
| 84145 | <1% | 58 | $683.02 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,563 | $681.95 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,891 | $680.67 |
| 82607 | <1% | 79 | $665.44 | |
| 10060 | <1% | 18 | $655.36 | |
| 85007 | <1% | 1,235 | $639.88 | |
| 82565 | <1% | 405 | $609.71 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,374 | $596.31 |
| A0429 | Emergency ambulance ride, basic life support | <1% | 15 | $546.70 |
| 93976 | <1% | 131 | $485.54 | |
| 85014 | <1% | 1,385 | $458.10 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 216 | $451.49 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,242 | $449.62 |
| 72070 | <1% | 14 | $444.79 | |
| G0008 | Administration of influenza virus vaccine | <1% | 49 | $437.42 |
| 87186 | <1% | 1,589 | $426.75 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,663 | $424.23 |
| 94664 | <1% | 324 | $423.48 | |
| 87077 | <1% | 590 | $411.39 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,505 | $369.14 |
| 87210 | <1% | 1,186 | $364.48 | |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 42 | $329.76 |
| 84439 | <1% | 181 | $324.33 | |
| 83615 | <1% | 2,108 | $319.78 | |
| 85730 | <1% | 762 | $289.17 | |
| 81025 | <1% | 1,545 | $287.37 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,464 | $263.72 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,380 | $250.57 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,108 | $207.89 |
| 85651 | <1% | 445 | $193.89 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,231 | $192.98 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,561 | $189.63 |
| 87807 | <1% | 677 | $176.37 | |
| 74022 | <1% | 75 | $171.48 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,630 | $159.39 |
| 87147 | <1% | 733 | $158.64 | |
| 82550 | <1% | 404 | $148.92 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 998 | $142.97 |
| 81015 | <1% | 159 | $136.18 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 920 | $135.86 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,799 | $133.52 |
| J1815 | Injection, insulin, per 5 units | <1% | 924 | $133.09 |
| 87088 | <1% | 562 | $112.12 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,100 | $110.78 |
| 73110 | <1% | 85 | $108.02 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 938 | $99.43 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 43 | $97.87 |
| 84703 | <1% | 108 | $96.63 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 104 | $91.48 |
| 73590 | <1% | 34 | $89.86 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 736 | $68.59 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 490 | $62.84 |
| 82947 | <1% | 77 | $59.01 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 442 | $57.97 |
| 73502 | <1% | 47 | $57.88 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 459 | $55.50 |
| 81003 | <1% | 140 | $54.71 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 418 | $54.10 |
| 36600 | <1% | 14 | $52.16 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 356 | $49.62 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 431 | $48.87 |
| 86803 | <1% | 27 | $36.33 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 290 | $33.37 |
| 84100 | <1% | 188 | $33.06 | |
| 84132 | <1% | 170 | $26.59 | |
| 80143 | <1% | 108 | $26.58 | |
| 87340 | <1% | 25 | $26.09 | |
| 86592 | <1% | 44 | $26.09 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 129 | $23.88 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 164 | $22.72 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 346 | $21.65 |
| 87184 | <1% | 104 | $21.46 | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 90 | $16.69 |
| 85652 | <1% | 16 | $15.68 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 94 | $14.26 |
| 80179 | <1% | 108 | $13.30 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 65 | $11.86 |
| 82570 | <1% | 14 | $10.84 | |
| 87205 | <1% | 120 | $8.71 | |
| 87070 | <1% | 83 | $8.70 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 46 | $6.25 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 52 | $5.29 |
| 96376 | <1% | 2,849 | $1.66 | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 0% | 2,328 | $0.00 |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | 0% | 18 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 18 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 231 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 46 | $0.00 |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 0% | 28 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 27 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 13 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 15 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 17 | $0.00 |
| 84295 | 0% | 15 | $0.00 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 0% | 13 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 1,340 | $0.00 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 0% | 12 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 182 | $0.00 |
| 82330 | 0% | 16 | $0.00 | |
| 86762 | 0% | 13 | $0.00 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 20 | $0.00 |
| G1011 | Clinical decision support mechanism, qualified tool not otherwise specified, as defined by the medicare appropriate use criteria program | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialADDISON, LEWIS (CFO)
| Provider | Location | Paid |
|---|---|---|
| Centra Health INC | Lynchburg, VA | $78.57M |
| Centra Medical Group, LLC | Lynchburg, VA | $60.16M |
| Centra Health INC | Lynchburg, VA | $5.20M |
| Centra Health INC | Lynchburg, VA | $2.82M |
| Centra Health INC | Lynchburg, VA | $2.35M |
| Centra Health INC | Lynchburg, VA | $2.04M |
| Centra Health INC | Lynchburg, VA | $1.59M |
| Centra Health INC | Lynchburg, VA | $205K |
| Centra Health, INC. | Lynchburg, VA | $13K |
| Centra Medical Group, LLC | Lynchburg, VA | $12K |
| Centra Health INC | Lynchburg, VA | $7K |
| Centra Medical Group, LLC | Lynchburg, VA | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.